3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
selpercatinib
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
ribociclib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Cyclophosphamide
2
Alpelisib
2
vandetanib
1
tivozanib
1
tipifarnib
1
temsirolimus
1
romidepsin
1
pembrolizumab
1
gadoteridol
1
gadoterate meglumine
1
gadolinium ethoxybenzyl DTPA
1
gadodiamide
1
gadobutrol
1
gadobenic acid
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
entrectinib
1
entinostat
1
avelumab
1
atezolizumab
1
alectinib
1
aldesleukin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
gadoterate meglumine
×
Endocrine
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled